SEC ownership of Cue Biopharma, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001645460.

Comparable stake leader

Bleichroeder LP

Disclosed value leader

Shao-Lee Lin

Comparable rows

50/50

Latest evidence

13 Aug 2026

Top shareholders Insider holders Latest transactions
Public ticker
CUE on Nasdaq
Parsed ownership sources
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
Bleichroeder LP
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Bleichroeder LP
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
13 Aug 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001645460
Issuer location
Boston, MA

Ownership snapshot

Top shareholders of Cue Biopharma, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bleichroeder LP
Disclosed value leader
Shao-Lee Lin
Comparable rows
50/50
Latest evidence
13 Aug 2026
13F 13D/G 3/4/5 Lead comparable stake: 10% 13D/G row: Bleichroeder LP Showing 1-8 of 50 holder rows.

Quick read

Bleichroeder LP leads the comparable SEC ownership view at 10%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bleichroeder LP's linked filing trail.
Comparable ownership Top 5
Bleichroeder LP 10%
DRIEHAUS CAPITAL MANAGEMENT LLC 7%
Shao-Lee Lin 6.2%
Mark E. Strome 5%
Slate Path Capital LP 1.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bleichroeder LP
13F 13D/G
Company
13F 13D/G
10%
from 13D/G
$11,698,724
370,682 shares
 — 30 Jun 2026
DRIEHAUS CAPITAL MANAGEMENT LLC
13D/G 13F
Company
13D/G 13F
7%
$10,745,056
292,144 shares
 $0 30 Jun 2026
Shao-Lee Lin
3/4/5 13D/G
Chief Executive Officer, Director
3/4/5 13D/G
6.2%
from 13D/G
$20,812,732
1,497,428 shares
mixed-class rows
 -$1,606,562 12 Aug 2026
Mark E. Strome
13D/G
13D/G
5%
$1,862,968
2,166,242 shares
 $0 14 Nov 2022
Slate Path Capital LP
13D/G
13D/G
1.4%
$790,199
918,836 shares
 $0 31 Dec 2024
Sumita Ray
3/4/5
Chief Legal Compliance Officer, Corporate Secretary
3/4/5
1.6%
$3,690,305
118,545 shares
 -$265,628 13 Aug 2026
Michael Vincent Meluzio
3/4/5
VP, Prin. Accounting Officer
3/4/5
0.65%
$1,524,155
48,961 shares
 -$169,324 13 Aug 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
2.1%
$5,103,252
161,700 shares
 — 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$1,941,767.

Buys
$99,747
Insiders: 1
Sells
$2,041,514
Insiders: 3
Net
-$1,941,767
Shares: +251,142
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 323,857 Shares: 72,715
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 72,715 $0 $2,041,514 -$2,041,514
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 323,857 0 $99,747 $0 +$99,747

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 28 reporting-owner rows connected to Cue Biopharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
28
Largest Forms 3/4/5 holder
Shao-Lee Lin
Net 12M change
-$1,941,767
Latest report
13 Aug 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Shao-Lee Lin Chief Executive Officer, Director $20,812,732 -$1,606,562 -7.2% Filing P/S 12 Aug 2026
Sumita Ray Chief Legal Compliance Officer, Corporate Secretary $3,690,305 -$265,628 -6.7% Filing P/S 13 Aug 2026
Michael J. Fox Director $3,036,000 Mixed 05 Jun 2024
Cameron Gray Director $1,896,255 Mixed 14 Jun 2022
Michael Vincent Meluzio VP, Prin. Accounting Officer $1,524,155 -$169,324 -10% Filing P/S 13 Aug 2026
Pasha Sarraf Director $887,528 +$99,747 +13% Mixed 09 Jul 2026
Pamela Garzone Director $574,560 Mixed 09 Jul 2026
Anish Suri President And Cso $374,361 Filing P/S 05 Jun 2024
Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director $169,515 Filing P/S 21 Mar 2025
James M. Ahlers Chief Financial Officer $14,025 Median 30 Jul 2026
Dominique Christian Borie Chief Medical Officer, Head of Research & Development $9,500 Mixed 13 Jul 2026
Viola Mong Meehan Director $6,575 Mixed 09 Jul 2026
Daniel A. Camardo Director $6,575 Mixed 09 Jul 2026
Tamar D. Howson Director Mixed 03 Jan 2023
Jill Marie Broadfoot Director Mixed 02 Jan 2026
Aaron G.l. Fletcher Director Mixed 03 Jan 2023
Kenneth Pienta Chief Medical Officer Mixed 25 Mar 2022
Usman Azam CHIEF EXECUTIVE OFFICER, Director Mixed 29 Sep 2025
Daniel G. Baker Chief Development Officer Mixed 09 Apr 2026
Colin Sandercock Svp, General Counsel Mixed 09 Apr 2026

Recent insider transactions for Cue Biopharma, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Sumita Ray CUE Common Stock Sale -6.93% $265,628 $30.09 -8,829 118,545 13 Aug 2026 Direct
Sumita Ray CUE Common Stock Options Exercise 16.7% 18,196 127,374 13 Aug 2026 Direct
Sumita Ray CUE Common Stock Options Exercise -33.3% -18,196 36,393 13 Aug 2026 Direct
Michael Vincent Meluzio CUE Common Stock Sale -10.3% $169,324 $30.09 -5,628 48,961 13 Aug 2026 Direct
Michael Vincent Meluzio CUE Common Stock Options Exercise 33.3% 13,647 54,589 13 Aug 2026 Direct
Michael Vincent Meluzio CUE Common Stock Options Exercise -33.3% -13,647 27,295 13 Aug 2026 Direct
Shao-Lee Lin CUE Common Stock Sale -2.52% $522,573 $28.62 -18,258 705,995 13 Aug 2026 Direct
Shao-Lee Lin CUE Common Stock Sale -5.23% $1,083,989 $27.10 -40,000 724,253 12 Aug 2026 Direct
Shao-Lee Lin CUE Common Stock Options Exercise 16.7% 109,179 764,253 12 Aug 2026 Direct
Shao-Lee Lin CUE Common Stock Options Exercise -33.3% -109,179 218,358 12 Aug 2026 Direct
James M. Ahlers CUE Common Stock Award 25,500 25,500 30 Jul 2026 Direct
James M. Ahlers CUE Stock Option (Right to Buy) Award 51,000 51,000 30 Jul 2026 Direct
Dominique Christian Borie CUE Common Stock Award 31,500 31,500 13 Jul 2026 Direct
Dominique Christian Borie CUE Stock Option (Right to Buy) Award 63,000 63,000 13 Jul 2026 Direct
Pasha Sarraf CUE Common Stock Award 170.4% 18,400 29,195 09 Jul 2026 Direct
Pamela Garzone CUE Common Stock Award 18,900 18,900 09 Jul 2026 Direct
Daniel A. Camardo CUE Common Stock Award 21,800 21,800 09 Jul 2026 Direct
Viola Mong Meehan CUE Common Stock Award 21,800 21,800 09 Jul 2026 Direct
Michael Vincent Meluzio CUE Common Stock Award 40,942 40,942 09 Jul 2026 Direct
Michael Vincent Meluzio CUE Common Stock Award 40,942 40,942 09 Jul 2026 Direct
Sumita Ray CUE Common Stock Award 100% 54,589 109,178 09 Jul 2026 Direct
Sumita Ray CUE Common Stock Award 54,589 54,589 09 Jul 2026 Direct
Shao-Lee Lin CUE Common Stock Award 100% 327,537 655,074 09 Jul 2026 Direct
Shao-Lee Lin CUE Common Stock Award 327,537 327,537 09 Jul 2026 Direct
Shao-Lee Lin CUE Common Stock Warrants (Right to Buy) Award 45,453 45,453 01 Jun 2026 See footnote
Shao-Lee Lin CUE Pre-Funded Warrants (Right to Buy) Award 90,906 90,906 01 Jun 2026 See footnote
Shao-Lee Lin CUE Common Stock Warrants (Right to Buy) Purchase 45,453 45,453 01 Jun 2026 See footnote
Shao-Lee Lin CUE Pre-Funded Warrants (Right to Buy) Purchase 90,906 90,906 01 Jun 2026 See footnote
Daniel A. Camardo CUE Stock Option (Right to Buy) Award 1,626 1,626 30 May 2026 Direct
Viola Mong Meehan CUE Stock Option (Right to Buy) Award 1,626 1,626 30 May 2026 Direct
Shao-Lee Lin CUE Common Stock Award 327,537 327,537 03 May 2026 Direct
Shao-Lee Lin CUE Stock Option (right to buy) Award 655,074 655,074 03 May 2026 Direct
Colin Sandercock CUE Stock Option (right to buy) Award 200,000 200,000 09 Apr 2026 Direct
Lucinda Warren CUE Stock Option (right to buy) Award 250,000 250,000 09 Apr 2026 Direct
Daniel G. Baker CUE Stock Option (right to buy) Award 100,000 100,000 09 Apr 2026 Direct
Peter A. Kiener CUE Stock Option (right to buy) Award 24,400 24,400 02 Jan 2026 Direct
Jill Marie Broadfoot CUE Stock Option (right to buy) Award 24,400 24,400 02 Jan 2026 Direct
Pamela Garzone CUE Stock Option (right to buy) Award 24,400 24,400 02 Jan 2026 Direct
Frank Morich CUE Stock Option (right to buy) Award 24,400 24,400 02 Jan 2026 Direct
Patrick Verheyen CUE Stock Option (right to buy) Award 24,400 24,400 02 Jan 2026 Direct
Pasha Sarraf CUE Stock Option (right to buy) Award 24,400 24,400 02 Jan 2026 Direct
Pasha Sarraf CUE Common Stock Purchase $99,747 $0.3080 323,857 323,857 30 Dec 2025 Direct
Colin Sandercock CUE Stock Option (right to buy) Award 70,000 70,000 03 Dec 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .